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Abstract
Gastrointestinal endoscopy (GIE) is a procedure for diagnosis and treatment of
gastrointestinal tract abnormalities. This procedure requires some forms of anesthe‐
sia. The goal of procedural anesthesia is safe, effective control of pain and anxiety, as
well as an appropriate degree of memory loss or reduced awareness. Generally, the
majority of GIE procedures are performed by using topical anesthesia and intravenous
sedation. General anesthesia is carried out in long and invasive procedures such as
endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, and small
bowel enteroscopy, as well in patients with history of failed sedation or drug and
substance abuse, uncooperative or pediatric patients, and patients with cardiorespir‐
atory system instabilities. The appropriate anesthetic agents for GIE procedures could
be short acting, rapid onset with little adverse effects and also improved safety
profiles. To date, the new anesthetic drugs and monitoring equipments for safety and
efficacy are available. The present review focuses on pre-anesthetic assessment,
anesthetic drugs used, monitoring practices, and post-anesthesia care for anesthesia
innovations in GIE procedures.
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1. Introduction
Anesthesia is one of the important components of gastrointestinal endoscopic (GIE) proce‐
dures. The aim of anesthesia for these procedures is to improve patient’s comfort and endo‐
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scopic practice as well as patient and endoscopist satisfaction. The requirement for anesthesia
is dependent on the type and duration of endoscopy, experience of endoscopist, and patient’s
physical status. The anesthetic regimens for GIE procedures are quite different. Several
guidelines from American Society of Anesthesiologists (ASA) [1] and American Academy of
Pediatrics [2] are established. Appropriate pre-anesthetic assessment, anesthetic drugs used,
monitoring practices and post-anesthesia care for anesthesia in GIE procedures are essential.
1.1. Pre-procedure assessment
All patients scheduled to receive anesthesia/sedation should have a history and appropriate
physical examination. Several risk factors including history of obstructive sleep apnea, alcohol
or drug abuse, and history of adverse reaction to previous anesthesia/sedation are investigated.
The patient physical status should be classified according to the ASA. The pregnancy test is
recommended in women of childbearing age [3]. Consequently, written consent should be
obtained. An anesthesia consultation should be done in high-risk patients including patients
with respiratory or hemodynamic instability, obstructive sleep apnea, and high-risk airway
management, as well as patients with ASA physical status >III and history of anesthesia-related
adverse events.
2. Monitoring
Cardiorespiratory-related adverse events are a leading cause of morbidity and mortality
associated with GIE procedures. Continuous monitoring of anesthetized patients is very
important for safety. The physicians need to monitor the patients’ status throughout the
procedure. Clinical observations including pattern of respiration, skin or mucosa color, and
level or depth of anesthesia are continuously observed.
2.1. Pulse oximetry
Pulse oximetry is a noninvasive device for continuous measurement of arterial oxygen
saturation. Because clinical observation alone is inaccurate in the detection of hypoxemia, pulse
oximetry has become a standard of care during GIE procedures. Oxygen saturation levels
under 90% must be treated. However, pulse oximetry and oxygen supplementation do not
diminish the severity or incidence of cardiorespiratory complications. In addition, oxygen
desaturation is relatively a late sign [4].
2.2. Capnography
Moreover, pulse oximetry and clinical observation cannot detect the development of hyper‐
capnea. Capnography has been utilized to permit the safe titration of propofol by a qualified
gastroenterologist during invasive procedures such as endoscopic retrograde cholangiopan‐
creatography (ERCP) and endoscopic ultrasonography (EUS).
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2.3. Noninvasive blood pressure
Blood pressure and heart rate are important parameters of cardiovascular monitoring. The
alterations of blood pressure are mediated by the depressive effects of anesthetic agents.
Baseline hemodynamic parameters also provide useful information of the effects of various
medical conditions. Generally, blood pressure and heart rate will be documented before
anesthesia, and at least 5 min for deep sedation and general anesthesia, as well as every 15 min
for mild and moderate sedation. Blood pressure is more likely to predict increasing and
decreasing doses of anesthetic drugs.
2.4. Electrocardiography
The use of electrocardiography (ECG) was aimed to detect cardiac arrhythmias in high-risk
patients undergoing anesthesia. However, the use of ECG during GIE procedure remains
controversial [6]. American Society for Gastrointestinal Endoscopy (ASGE) and ASA practice
guidelines recommend the use of ECG during GIE anesthesia in patients with significant
cardiovascular diseases or arrhythmias. However, ECG is not recommended for routine use
of ECG in patients with ASA physical status I or II [1, 4, 7].
2.5. Other monitors
Other monitors such as invasive arterial blood pressure, central venous pressure (CVP), and
pulmonary arterial catheterization (PAC) are infrequently used during GIE anesthesia.
However, these invasive monitors should be used in some high-risk patients including patients
with severe hemodynamic instabilities and patients with shock.
2.6. Bispectral index monitoring
The depth of anesthesia cannot be reliably judged by clinical assessments alone. Currently, the
Bispectral (BIS) index has been reported to be more accurate in measurement of the depth of
anesthesia. The BIS scale ranges from 0 to 100 (0, no cortical activity or coma; 40-60, uncon‐
scious; 70-90, varying levels of conscious sedation; 100, fully awake). In the past, BIS monitor
was used to assess the patient consciousness during general anesthesia [4, 8]. To date, its use
has subsequently expanded into the procedural sedation technique. However, the use of BIS
during GIE procedures remains a controversial issue.
The usefulness of BIS monitoring for GIE procedure was confirmed by the study of Bower and
colleagues. This study showed the correlation of BIS index and the Observer’s Assessment of
Alertness/Sedation (OAA/S) scale for sedation during GIE procedures. It also suggested that
a bispectral index near 82 corresponded with acceptable sedation level for GIE procedure [9].
Al-Sammak and coworkers compared BIS with clinical assessment for sedation during ERCP
procedure in pediatric patients. The duration of sedation, recovery period, patient satisfaction,
and total dose of sedative agents in the BIS group were better than in the clinical assessment
group. This study demonstrated that BIS might be a valuable monitor for safe level of sedation
and endoscopist’s satisfaction during ERCP [10]. Another study also showed that BIS moni‐
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toring guided to a decrease in the propofol dose for sedation in ERCP procedures. Mean BIS
values throughout the procedure and during the maintenance period of sedation were 61.68
± 7.5 and 53.73 ± 8.67, respectively [11].
In contrast, several reports demonstrated that BIS index had low accuracy for detecting deep
sedation and it was not helpful for titrating propofol to an adequate depth of sedation level.
For example, Chen and Rex evaluated the utility of BIS as a monitoring device for nurse-
administered propofol sedation (NAPS) during colonoscopic procedure. The study showed
the mean time required to accomplish BIS values ≤60 was significantly longer than the mean
time required to achieve an Observer’s Assessment of Alertness/Sedation score of 1 (deep
sedation). Additionally, there was also a lag time between the time required from the last dose
of propofol and the time returned to baseline. The authors concluded that BIS index was not
a useful device in titrating propofol to an adequate depth of sedation level [12].
Drake and coworkers also confirmed that BIS did not lead to the reduction in mean propofol
dose or recovery time when used for sedation in colonoscopy [13]. Moreover, an observational
study also showed that BIS index had a low accuracy for detecting deep sedation because of
an overlap of scores across the sedation levels. Further improvements in BIS are needed to
differentiate deep from moderate sedation for GIE procedures [14].
2.7. NarcotrendTM
NarcotrendTM accomplishes a computerized analysis of the raw EEG. A statistical algorithm is
used for analysis, resulting in a six-stage classification from A (awake) to F (general anesthesia/
coma) and 14 substages [4, 15]. Wehrmann and colleagues evaluated 80 patients who under‐
went ERCP procedures by using EEG monitoring and clinical assessment for sedation. Their
study demonstrated that mean propofol dose, decrease in blood pressure, and recovery time
in the EEG monitoring group were significantly lower than in the clinical assessment group.
The authors confirmed that EEG monitoring permitted more effective titration of propofol
dosage for sedation during ERCP procedures and was associated with more rapidly patient
recovery [16].
My previous study used the NarcotrendTM to guide the depth of sedation for ERCP procedure.
NarcotrendTM monitoring was an effective tool for maintenance of the depth of sedation level
in this procedure [17]. The other study compared the clinical efficacy of NarcotrendTM
monitoring and clinical assessment used to provide deep sedation in patients who underwent
ERCP procedure. In the study, Modified Observer’s Assessment of Alertness/Sedation scale 1
or 2 and the NarcotrendTM index 47-56 to 57-64 were maintained during the procedure. All
endoscopies were completed successfully. Both NarcotrendTM and clinical-assessment-guided
propofol deep sedation were equally safe and effective as well as demonstrated comparable
propofol dose and recovery time. However, the NarcotrendTM-guided sedation showed lower
hemodynamic changes and fewer complications compared with the clinical-assessment-
guided sedation [18].
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3. Anesthetic technique
3.1. Topical anesthesia
Esophagogastroduodenoscopy (EGD) is  commonly performed by using topical  pharyng‐
eal anesthesia. Topical lidocaine is normally used as pretreatment for pharyngeal anesthe‐
sia. My previous study evaluated the clinical efficacy of topical viscous lidocaine solution
and lidocaine spray when each was used as a single agent for unsedated EGD [19].  All
patients were randomized into the viscous lidocaine (V) group (n = 930) or the lidocaine
spray (S) group (n = 934). The results showed the procedure was successfully completed
in 868 patients from group V and 931 patients from group S. Patient’s and endoscopist’s
satisfaction, pain score, patient tolerance, and ease of intubation in group S were significant‐
ly  better  than those  in  group V.  Additionally,  adverse  events  in  group S  also  occurred
significantly  lower  than group V.  This  study demonstrated that  the  use  of  topical  lido‐
caine spray was shown to be a  better  form of  pharyngeal  anesthesia  than viscous lido‐
caine solution in unsedated EGD procedure [19].
Consequently, the use of posterior lingual lidocaine swab can apply for EGD procedure.
Soweid and colleagues evaluated the effect of posterior lingual lidocaine swab in 80 patients
who underwent diagnostic EGD procedures on patient tolerance, the ease of performance of
EGD procedure, and to determine if such use would decrease the need for intravenous sedation
[20]. The result of their study demonstrated that patients in the lidocaine swab group tolerated
the procedure better than those in the lidocaine spray group. The procedural difficulty and
the need of intravenous sedation in the lidocaine swab group were lower than in the lidocaine
spray group. Additionally, the patients and the endoscopists in the lidocaine swab group were
more satisfied than in the lidocaine spray group. They suggested the use of posterior lingual
lidocaine swab for EGD procedure because of patient comfort and tolerance, endoscopist
satisfaction, and reduction of the need for intravenous sedation.
Ramirez and coworkers also compared the effect of glossopharyngeal nerve block and topical
anesthetic agent for EGD procedure [21]. The aim of the study was to evaluate the sedation,
tolerance to the procedure, hemodynamic stability, and the adverse events. They performed
a clinical trial in a total of 100 patients who underwent EGD procedures. All patients in both
arms also received intravenous midazolam. The procedures were reported without discomfort
in 48 patients (88%) in the glossopharyngeal nerve block group and 32 patients (64%) in the
topical anesthetic group. There were no significant differences in the incidence of nausea and
retching in both groups. The study confirmed that the use of glossopharyngeal nerve block
provided greater patient comfort and tolerance as well as also diminished the need for sedation
in EGD patients [21].
3.2. Intravenous sedation
Sedation for GIE procedure can be safely and effectively performed with a multidrug regimen
utilizing anesthesiologist or nonanesthetic personnel with appropriate monitoring. Currently,
sedation practices for GIE procedures vary widely. The need for sedation is decided by the
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type of endoscopy, duration of procedure, degree of endoscopic difficulty, patient physical
status, and physician’s preferences. However, the sedation regimen for GIE procedures is still
varied. Benzodiazepines and opioids are commonly used by nonanesthetic personnel. In
contrast, propofol in combination with opioids and/or benzodiazepines is usually used by
anesthetic personnel.
3.3. General anesthesia
The choice of anesthetic technique for GIE procedure depends on the patient and the type of
procedure. General anesthesia is commonly utilized in patients with ASA physical status >III
and patients with cardiorespiratory instability, as well as in long duration and complicated
procedures. Traditionally, tracheal intubation is also performed when general anesthesia is
used. An anesthesiologist usually uses balanced anesthesia technique including opioid,
inhalation agent, and neuromuscular blocking drug. The majority of these anesthetic agents
have short-acting and short-duration properties.
4. Anesthesia innovative techniques
4.1. Target-controlled infusion
Target-controlled infusion (TCI) is a computer-controlled open-loop administration of
anesthetic drugs. A continuous infusion technique uses a pharmacokinetic model to predict
the patient plasma and effect site concentrations from the infusion design and allows the
anesthesiologist to target a selected concentration. The device computes the appropriate
infusion system to accomplish this concentration [22]. The TCI rapidly attains and maintains
a predefined plasma or effect site concentration of the anesthetic drug. An appropriate target
concentration for achieving the desired clinical endpoint is selected. The TCI delivery system
performs better than the manual system. Presently, TCI devices for propofol administration
are approved in several countries.
Mazanikov and colleagues compared TCI (initial targeted effect-site concentration 2 mcg/mL)
with patient-controlled sedation (PCS) (single bolus 1 mL, lockout time set at zero) in 82
patients who underwent elective ERCP procedures. Alfentanil was supplemented if needed.
All procedures were performed successfully. Mean consumption of propofol and the recovery
time in the TCI group was significantly greater than in the PCS group. However, mean
consumption of alfentanil in both groups was comparable. The authors concluded that there
were no benefits of TCI over PCS for propofol administration in ERCP procedures [23].
4.2. Patient-controlled sedation
Because of interindividual variability, new techniques of administration for sedation have been
developed. Patient-controlled sedation (PCS) devices deliver a predefined bolus of intrave‐
nous drug during a defined time with or without a lockout interval. A prospective, random‐
ized, controlled study compared the use of PCS with propofol and remifentanil and the
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anesthesiologist-administered propofol sedation for 80 elective ERCP patients. Sedation level
was assessed every 5 min by using Ramsay and Gillham sedation scores. All ERCP patients
were completely successful except two patients in the PCS group. Mean level of sedation and
total propofol consumption in the PCS group were significantly lower than in the anesthesi‐
ologist-administered propofol group. However, patient and endoscopist satisfaction were
equally high in both groups. The study confirmed that PCS with propofol and remifentanil
was a safe and well-accepted sedation technique for ERCP patients [24].
Moreover, the use of PCS with propofol and remifentanil has been compared with fentanyl
and midazolam for sedation in patients who underwent colonoscopy by Mandel and collea‐
gues [25]. Their study demonstrated that time to sedation and the recovery time in the PCS
with the propofol and remifentanil group were significantly shorter than in the PCS with the
fentanyl and midazolam group. However, the perceptions of patients, nurses and endoscopists
were comparable between the two groups.
Procedural sedation in cirrhotic patients is challenged. Titration of sedative and analgesic
drugs is needed for an optimal sedation level. The use of PCS for sedation in these patients is
an alternative technique. Although, dexmedetomidine is suggested for procedural sedation
and reported effective for alcohol withdrawal, the efficacy of dexmedetomidine as a sole
anesthetic agent is controversial. Mazanikov and coworkers evaluated 50 patients with chronic
alcoholism scheduled for elective ERCP procedures. All patients in the PCS with propofol and
alfentanil group were successfully sedated, and in 19 of 25 (76%) patients in the dexmedeto‐
midine group. They also suggested that a loading dose of dexmedetomidine 1 mcg/kg over 10
min, followed by continuous intravenous infusion 0.7 mcg/kg/h was insufficient for the ERCP
procedure. In addition, dexmedetomidine was also related with prolonged recovery [26].
4.3. Computer-assisted personalized sedation system
The use of propofol for sedation in GIE procedures may allow for better quality of sedation
and faster recovery. Computer-assisted personalized sedation system (CAPS) is based on the
patient response to stimulation and physiologic profiles. It presents an attractive means of
delivering safe and effective doses of propofol. The closed-loop target-controlled system or
continuous EEG recordings are used to assess the degree of sedation. Patient-controlled
platforms may also be used. These devices may help physicians titrating propofol adminis‐
tration and controlling the physiological functions [27].
The SEDASYS System is a CAPS integrating propofol delivery with patient monitoring to allow
physicians to safely administer propofol. The efficacy and safety of this system for sedation
during GIE procedures was evaluated and compared with the combination of benzodiazepine
and opioid in 1000 adult patients with ASA physical status class I-III. All patients were sedated
in mild to moderate depth of sedation level. The study demonstrated that SEDASYS system
was safe and effective for sedation during EGD and colonoscopic procedures. Additionally,
patient and physician satisfaction as well as recovery time in the SEDASYS group were
significantly better than patients in the combination of benzodiazepine and opioid group [28].
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The use of inadequate sedative agents results in over and under depth of sedation. The use of
CAPS for administration of propofol by nonanesthetic personnel achieving mild to moderate
sedation in patients who underwent GIE procedures was evaluated by Pambianco and
coworkers [29]. This study showed that propofol administration in mild or moderate sedation
level by nonanesthetic personnel used with CAPS system in patients who underwent EGD
and colonoscopic procedures was safe and effective. Moreover, low propofol dosage and short
recovery time were noted.
4.4. Closed-loop administration of anesthesia
Closed-loop administration of anesthesia systems can provide anesthesia automatically and
its effect feedback controlled. This system contains a central system, a target control device
such as syringe pump, vaporizer, and other drug delivery systems [30]. Currently, there are
several closed-loop administration systems for neuromuscular blockade, depth of anesthesia,
and pain control during decreased levels of consciousness. In addition, McSleepy is also a
closed-loop control system that displays the patient’s depth of consciousness, muscular
movement during surgery, and the level of pain [30].
4.5. Teleanesthesia
Teleanesthesia is the use of telemedicine technology in anesthetic management including
preoperative assessment at distance, video consultation, and performing anesthesia in remote
locations where experienced anesthesiologists are not always present [30, 31]. The impact of
telemedicine pre-anesthesia evaluation on periprocedural processes was confirmed by
Applegate II and colleagues. Their study demonstrated that telemedicine pre-anesthesia
evaluation offered patients time- and cost-saving benefits without more surgical delay.
Moreover, telemedicine and in-person assessments were comparable, with high patient and
physician satisfaction [32].
5. Anesthetic agents
5.1. Local anesthetic agents
Generally, lidocaine is the most common local anesthetic agent used for GIE procedure. The
viscous lidocaine solution and lidocaine spray are usually performed for upper GIE procedure.
In addition, lidocaine gel or jelly is frequently employed for lower GIE procedure. Recently,
lidocaine lozenge has been tried to use for EGD procedure. Mogensen and colleagues evalu‐
ated the effect and acceptance of a lidocaine lozenge compared with a lidocaine viscous oral
solution as pharyngeal anesthesia before EGD [33]. The 110 adult patients were randomized
to receive either 100 mg lidocaine as a lozenge or 5 mL lidocaine viscous solution 2%. Supple‐
mental intravenous midazolam was administered if needed. They concluded that the lozenge
could reduce gag reflex and patients’ discomfort, and improved patients’ acceptance during
the procedure. In addition, the lozenge form had also a good taste [33]. Another study of the
lidocaine lozenge used for pharyngeal anesthesia in EGD procedure has been reported by
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Tumminakatte and Nagaraj [34]. The authors compared the efficacy, safety, and patient
comfort for the lidocaine lozenge and lidocaine viscous as a single agent before EGD proce‐
dure. This study showed that lidocaine lozenge was effective and safe for pharyngeal anes‐
thesia before EGD procedure. It was relatively better than lidocaine viscous in terms of lesser
discomfort and procedural difficulty as well as increased tolerability of the EGD procedure
[34].
Moreover, topical bupivacaine could be used as pretreatment for pharyngeal anesthesia in
unsedated EGD. The effect of a bupivacaine lozenge as pharyngeal anesthesia and a lidocaine
spray before EGD was assessed by Salale and coworkers [35]. Ninety-nine adult patients were
randomized to receive either a bupivacaine lozenge or lidocaine spray. Patient discomfort and
the acceptance of gag reflex during EGD procedures were evaluated. The results showed that
patient discomfort and gag reflex during procedure in the bupivacaine lozenge group were
significantly lower than the lidocaine spray group. The authors also suggested that bupiva‐
caine lozenge for topical pharyngeal anesthesia before an unsedated EGD procedure verified
to be a superior option as compared with lidocaine spray [35].
Chan and colleagues studied the effectiveness of 10% lidocaine pump spray plus plain Strepsils
and Strepsils anesthetic lozenge plus distilled water spray for EGD procedure in terms of
patient tolerance, taste of anesthetic agent, intensity of numbness, amount of cough or gag,
and the degree of discomfort at esophageal intubation. They concluded that topical lidocaine
spray was superior to the flavored anesthetic lozenge as a topical pharyngeal anesthesia in
unsedated EGD procedure [36]. Furthermore, the safety and efficacy of a lidocaine lollipop as
single-agent anesthesia for EGD has been evaluated by Ayoub and coworkers [37]. The main
outcome variables of the study were the success rate and safety of local anesthesia by using
lidocaine lollipop in addition to the need for intravenous sedation. Their study showed that
lidocaine lollipop, a favorable form of pharyngeal anesthesia, was safe and well tolerated for
EGD procedure.
5.2. Benzodiazepines
5.2.1. Midazolam
Midazolam is one of the most common drugs used for sedation during GIE procedures. It is a
rapid-onset, short duration of action, and water-soluble benzodiazepine with anxiolytic,
amnesic, sedative, muscle relaxant, and anticonvulsant properties. These actions are due to
the effect of binding to gamma-amino butyric acid receptors in the central nervous system.
Midazolam has few adverse effects. Respiratory depression is the most important adverse
effect and is synergistic when used in combination with opioids. The standard dose in adult
patients is 0.015-0.06 mg/kg [38].
5.3. Opioids
5.3.1. Fentanyl
Fentanyl is a potent synthetic opioid and also commonly used for GIE procedures. It has a
rapid onset, short duration of action, and lack of direct myocardial depressant effects. The
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onset of action is 30–60 s, and the duration of action is 30–45 min. Generally, the dose for GIE
procedure is usually 1–2 mcg/kg, with a maximum dose of 100–150 mcg in adult healthy
patients. Because of its analgesic effect, fentanyl is commonly used for therapeutic GIE
procedures. Of late, the combination of fentanyl and midazolam is an accepted regimen with
a safety profile [39-41]. However, fentanyl can cause respiratory depression including apnea
as well as nausea and vomiting. It can reduce the heart rate.
5.3.2. Remifentanil
Remifentanil is a fentanyl analog with a methyl ester group and is hydrolyzed by plasma and
tissue esterases. Its metabolism is not affected by genetics, age, hepatic failure, and renal failure.
Its action is rapid. The use of remifentanil for sedation in GIE procedures is not entirely
recognized. Remifentanil is generally performed by using the continuous infusion technique.
The TCI of remifentanil is another preference. The combination of propofol and remifentanil
for sedation in GIE procedures is usually used. The study of Abu-Shahwan and Mack dem‐
onstrated the efficacy and safety of a combination of propofol and remifentanil for deep
sedation in children who underwent GIE procedures [42]. In their study, anesthesia was
induced with sevoflurane and nitrous oxide in oxygen, and was maintained with infusion of
propofol and remifentanil. All GIE procedures were successfully completed with no compli‐
cations. However, this combination of propofol and remifentanil demonstrated the reduction
of heart rate, blood pressure, and respiratory rate.
Remifentanil in TCI appears to be a satisfactory drug for sedation in GIE procedures. However,
propofol in TCI for GIE procedures demonstrates better sedation than remifentanil in TCI. This
issue was confirmed by Munoz and colleagues [43]. They compared remifentanil and propofol
in TCI for sedation in 69 patients during GIE procedures. The authors concluded that propofol
in TCI for sedation in patients who underwent GIE procedures seemed to be an adequate agent.
Additionally, propofol in TCI created less adverse effects and higher patient satisfaction than
remifentanil in TCI.
5.4. Remimazolam
Remimazolam is a rapidly acting intravenous sedative drug. It combines the properties of
midazolam  and  remifentanil.  Additionally,  its  tendency  to  cause  apnea  is  very  low.
Remimazolam has potential to be used as a sedative drug in the intensive care unit and as
a novel agent for procedural sedation [44, 45]. Recently, remimazolam was evaluated for
sedation in patients who underwent upper GIE procedures by Rogers and McDowell. This
clinical  trial  demonstrated that the time to recovery from sedation of remimazolam was
faster  and  more  reliable  than  midazolam  [46].  Moreover,  Worthington  and  colleagues
assessed the feasibility of remimazolam for sedation during colonoscopy and reversing the
sedative effects of remimazolam with flumazenil in 15 healthy volunteers. The sedation for
colonoscopy  was  successfully  completed  in  more  than  70%  of  subjects.  In  addition,  all
subjects rapidly reversed with flumazenil  and also rapidly recovered within 10 min. No
serious adverse events were observed [47].
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5.5. Propofol
Propofol has sedative, hypnotic, and anesthetic properties. However, it does not have analgesic
effects. Propofol rapidly crosses the blood–brain barrier. The onset of action is 30–60 s. Dose
reduction is needed in patients with cardiac dysfunction and in elderly patients. However, the
dose reduction of propofol in patients with moderately severe liver disease or renal failure is
not required. Propofol potentiates the effects of analgesic and sedative drugs. The advantage
of propofol has been demonstrated for therapeutic GIE procedures and not for diagnostic GIE
procedures.
Propofol in combination with opioid or benzodiazepine can cause significant cardiovascular
depression and may result in a deeper than expected depth of sedation because of its narrow
therapeutic window. Pain at the injection site is the most frequent local complication. Several
methods for propofol delivery have been used for GIE procedures. Generally, propofol is
administered intravenously as a repeated bolus injection, continuous infusion, or a mixture of
both. Currently, the nonanesthesiologist-administered propofol is a controversial issue and
also varies among countries.
5.5.1. Propofol for GIE procedures
Generally, propofol is usually used for various GIE procedures. A previous study confirmed
that sedation with propofol alone or propofol combined with fentanyl or midazolam in
children was safe and effective. However, the use of propofol alone provides lesser sedation
and ease of endoscopy than the use of propofol in combination with fentanyl or midazolam
[48]. In Siriraj GI Endoscopy Center, the combination of propofol, fentanyl, and/or midazolam
was usually used for GIE procedures even in pediatric patients. Moreover, our previous
studies also demonstrated the clinical effectiveness of an anesthesiologist-administered
sedation outside of the operating room for pediatric GIE procedures. Although, all sedation-
related complications were relatively high, all of these complications were transient and easily
treated [39, 40, 49, 50]. In terms of procedure-related complications, propofol-based sedation
does not increase the rate of colonoscopic perforation [51].
For invasive GIE procedures, propofol-based sedation for ERCP and percutaneous endoscopic
gastrostomy procedures in sick and elderly patients by anesthetic personnel with appropriate
monitoring was also safe and effective without any serious complications [52-54]. The safety
of propofol sedation for EUS with fine needle aspiration procedure was confirmed by Pagano
and coworkers [55]. The complication rates for propofol deep sedation and meperidine/
midazolam administered for moderate sedation were not significantly different. Furthermore,
propofol combined with fentanyl and midazolam is frequently used for GIE procedures
including EUS and small bowel enteroscopy [56-60].
5.5.2. Nurse-administered propofol
Several guidelines do not recommend the use of propofol for routine GIE procedures. The
safety and efficacy of propofol administered by registered nurses has been reported in a case
series including 2000 patients undergoing elective EGD and/or colonoscopy [61]. Another
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study demonstrated that trained nurse-administered propofol for GIE sedation in patients
with ASA class I, II, and III was safe and effective. The anesthetic support was assisted in 11
patients (0.4%) [62].
5.5.3. Gastroenterologist-administered propofol
Similar to qualified nurses, the gastroenterologist can administer propofol effectively. Several
guidelines recommend that gastroenterologist-administered propofol should be used to sedate
patients only at mild or moderate sedation levels. Additionally, the patients must have ASA
physical status not more than III. The study of Vargo and colleagues confirmed that gastro‐
enterologist-administered propofol for elective ERCP and EUS procedures resulted in the
reduction of propofol dosage and the improvement of recovery activity as well as the rapid
detection of respiratory depression. This study also demonstrated that gastroenterologist-
administered propofol should be a cost-effective sedation technique [63].
5.5.4. Anesthesiologist-administered propofol
Propofol is commonly used by anesthesiologists for anesthesia in GIE procedures. To date, the
use of propofol is still controversial. Propofol can be used by well-trained registered nurses or
physicians in some countries. However, in developing countries, propofol-based sedation is
performed by anesthesiologists or anesthetic nurses. Berzin and coworkers accomplished a
cohort study of sedation-related adverse events, patient- and procedure-related risk factors
associated with sedation, as well as endoscopist and patient satisfaction with anesthesiologist-
administered sedation in 528 patients who underwent ERCP procedures. The study confirmed
that anesthesiologist-administered sedation for ERCP patients was safe and effective. Cardi‐
orespiratory-related adverse events were generally minimal [64].
5.6. Fospropofol
Fospropofol is a water-soluble prodrug of propofol that is currently approved for sedation for
diagnostic and therapeutic procedures. It is characterized by a smooth and predictable rise
and decline rapidly observed following intravenous administration. It does not cause pain on
intravenous injection, but it has been associated with paresthesia in the perineal and perianal
area. However, fospropofol causes dose-dependent hypotension, respiratory depression, and
apnea. Generally, a standard of fospropofol sedation is 6.5 mg/kg. In high-risk and elderly
patients, a lower dose should be administered. Bergese and coworkers compared the efficacy
and safety of fospropofol in a dose of 4.875 mg/kg and 6.5 mg/kg for sedation in high-risk
elderly patients who underwent colonoscopy. This study showed that fospropofol in a dose
of 4.875 mg/kg for sedation in high-risk elderly patients who underwent colonoscopy was not
a clinically significant advantage. Fospropofol in a dose of 6.5 mg/kg was recommended in the
elderly, obese, and high-risk patients when used for moderate sedation [65].
5.7. Ketofol
Ketofol is the combination of ketamine and propofol in various concentrations. It isan agent
of choice for a variety of GIE procedures. Ketamine, a neuroleptic anesthetic agent, works on
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thalamocortical and limbic N-methyl-D-aspartate receptors. Ketamine stimulates the cardior‐
espiratory system. A direct effect increases cardiac output, arterial blood pressure, heart rate,
and central venous pressures [66]. In contrast, propofol has antiemetic, anxiolytic, hypnotic,
and anesthetic properties. Additionally, propofol has a short recovery time without an increase
of cardiorespiratory side effects. As a result, the combination of these two drugs has several
benefits because of hemodynamic stability, lack of respiratory depression, good recovery and
post-procedural analgesia. The safety and efficacy of ketofol as a sedoanalgesic agent are
dependent on the dose and the ratio of the mixture [67].
Ketofol is also commonly used for sedation during GIE procedures. My previous study
evaluated the clinical efficacy of the ketofol and propofol alone when each regimen is used as
sedative agents for colonoscopic procedure. A 194 patients were randomized into two groups;
97 patients in group PK received propofol and ketamine and 97 patients in group P received
propofol and normal saline for sedation. All patients were premedicated with 0.02–0.03
mg/kg of midazolam. All colonoscopic procedures were completely successful. There were no
significant differences in patient tolerance, hemodynamic parameters, recovery activity,
patient and endoscopist satisfaction, as well as the sedation-related adverse events between
the two groups. In addition, these adverse events were transient and mild in degree [68].
5.8. Dexmedetomidine
Dexmedetomidine is a specific central alpha-2 adrenoreceptor agonist with sedative and
analgesic properties. Dexmedetomidine has no effect at the GABA receptor, and is not
associated with significant respiratory depression. The patients can be sedated but are able to
be awakened to full consciousness easily. It induces a biphasic blood pressure response: high
doses cause hypertension, and lower doses cause hypotension and bradycardia. The other
disadvantages of dexmedetomidine include a slow onset and longer duration of action [42].
To date, the role of dexmedetomidine for GIE procedures is not entirely established and
remains a controversial issue. Samson and colleagues compared the sedation efficacy and the
hemodynamic effects of dexmedetomidine, midazolam, and propofol in 90 patients with ASA
physical status I or II, who underwent elective diagnostic upper GIE procedures. The results
demonstrated that endoscopist satisfaction level, recovery, and the hemodynamic stability in
the dexmedetomidine group were significantly better than in the midazolam and the propofol
groups [69]. However, dexmedetomidine alone is less effective than the combination of
propofol and fentanyl for moderate sedation during ERCP procedure [70]. Most of the patients
needed supplementary analgesic and sedative drugs to accomplish the depth of sedation level.
However, these findings do not allow us to conclude that propofol alone is better than
dexmedetomidine alone, because the conclusion was established for propofol combined with
fentanyl. Moreover, dexmedetomidine was associated with higher hemodynamic instability
and a prolonged recovery phase [70].
5.9. Ketodex
Ketamine is a dissociative anesthetic agent and works on thalamocortical and limbic N-methyl-
D-aspartate (NMDA) receptors. Its actions are described by catalepsy in which eyes remain
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open and there is slow nystagmic gaze while corneal and light reflexes remain intact. Direct
effects increase cardiac output, blood pressure, heart rate as well as pulmonary arterial and
central venous pressures, which stimulates the cardiorespiratory system. However, ketamine
produces unpleasant psychological effects including hallucinations, nightmares, and emer‐
gence reactions. Dexmedetomidine is a specific central alpha-2 adrenergic agonist that
decreases central presynaptic catecholamine release. It has no effect at the GABA receptor, and
is not associated with significant respiratory depression. Its properties of sedation, anxiolysis,
and analgesia together with its beneficial pharmacokinetics make it a valuable adjunct for
procedural and intensive care sedation [66].
The use of ketodex for GIE procedures was reported by Goyal and colleagues [71]. They used
a bolus dose of ketamine 2 mg/kg and dexmedetomidine 1 mcg/kg for upper GIE procedures
in pediatric patients. The results of the study showed that blood pressure, heart rate, and
oxygen saturation did not change significantly from the baseline. The airway interventions
were not used. In addition, there were also no laryngospasm and postprocedural shivering.
The delirium score was lower than 4 in all patients except for two cases. This case series
supported the use of ketodex was safe and clinically effective for upper GIE procedure in
pediatric patients [71].
5.10. Muscle relaxants
5.10.1. Cisatracurium
Cisatracurium, an isomer of atracurium, is about three times more potent than atracurium and
less tendency to release histamine than atracurium. It experiences spontaneous degradation
at physiological pH and temperature by Hofmann elimination. Liver disease does not appear
to have an effect on cisatracurium. Pharmacokinetics and pharmacodynamics of cisatracurium
in normal adult and liver transplant patients do not show clinically significant differences in
the recovery profiles [72]. Because of its beneficial properties, cisatracurium is a muscle
relaxant drug of choice for tracheal intubation and maintenance during general anesthesia in
GIE procedures [50, 59].
5.10.2. Rocuronium
Rocuronium is a steroidal nondepolarizing neuromuscular blocking drug and has a rapid
onset of action. It is a muscle relaxant drug of choice for tracheal intubation and maintenance
during general anesthesia in GIE procedures [50, 59, 73]. Rocuronium has emerged as an
alternative to succinylcholine for facilitating rapid tracheal intubation in full stomach patients.
It is predominantly useful as a relaxant agent for tracheal intubation in patients at risk of
hyperkalemia and patients with known or suspected increased intracranial or intraocular
pressure. However, rocuronium may be used cautiously in patients with impaired liver
function [74].
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5.11. Reversal drugs
5.11.1. Naloxone
Naloxone is a pure mu-opioid antagonist with a high affinity for the receptor. It can reverse
both the analgesic and respiratory effects of opioids [4, 42]. The standard dosage of intravenous
naloxone is 1–2 mcg/kg with a maximum dose of 0.1 mg/kg and up to 2 mg. However, naloxone
has a short duration of action and one dose typically only lasts for 30–45 min. Patients should
be monitored for at least 2 h after the last dose of naloxone. The adverse reactions of naloxone
include reversal of opioid withdrawal, nausea/vomiting, hypertension, tachycardia, pulmo‐
nary edema, and cardiac dysrhythmias.
5.11.2. Flumazenil
Flumazenil is a benzodiazepine antagonist. It is a highly specific benzodiazepine receptor
antagonist and can safely reverse the sedative and respiratory effects caused by benzodiaze‐
pines. The adult dose is 0.01 mg/kg and up to 1 mg. Its duration of action is just about 1 h.
However, this effect is reversible. Importantly, the patients should be observed for at least 2 h
after the administration of flumazenil [4, 42]. The adverse reactions of flumazenil consist of
sweating, flushing, nausea/vomiting, hiccup, agitation, abnormal vision, paresthesia, and
seizure.
5.12. Sugammadex
Sugammadex is a selective relaxant binding drug that quickly reverses the effects of amino‐
steroid neuromuscular blocking agents such as rocuronium and vecuronium. It was success‐
fully used to reverse rocuronium-induced neuromuscular block in patients where neostigmine
was insufficient. Dogan and colleagues investigated the efficacy of sugammadex after
unsatisfactory decurarization following neostigmine administration. This study was per‐
formed on 14 patients who experienced inadequate decurarization (TOF < 0.9) with neostig‐
mine after general anesthesia. A dose of 2 mg/kg of sugammadex was used. The result
confirmed that sugammadex was successfully performed to reverse rocuronium-induced
neuromuscular block in patients where neostigmine was insufficient [75]. The capability to
reverse a rocuronium-induced neuromuscular block at any stage and possibly to improve
patients’ safety might make sugammadex a very attractive drug for the use in day-case
anesthesia.
Another study compared the efficacy of sugammadex and neostigmine for the reversal of
vecuronium-induced neuromuscular blockade in elective surgical patients [76]. All patients,
ASA physical status I-III obtained a dose of 0.1 mg/kg vecuronium for tracheal intubation and
maintenance dose of 0.02–0.03 mg/kg if needed. Neuromuscular blockade was monitored by
using acceleromyography. At the end of surgery, patients were randomized to receive either
sugammadex 2 mg/kg or neostigmine 50 mcg/kg and glycopyrrolate 10 mcg/kg. The study
showed that mean recovery times to a TOF ratio of 0.8 and 0.7 in the sugammadex group were
significantly shorter than in the neostigmine group. No serious adverse events were noted.
Anesthesia Innovations for Endoscopy of Gastrointestinal Tract
http://dx.doi.org/10.5772/60730
53
The authors concluded that sugammadex presented significantly quicker reversal of vecuro‐
nium-induced neuromuscular blockade compared with neostigmine [76].
5.13. Inhalation agents
5.13.1. Sevoflurane
Sevoflurane is an inhalation agent with ideal properties for deep sedation during GIE proce‐
dures in pediatric patients. In addition, it is commonly used for balanced general anesthesia.
A retrospective study reviewed data from children receiving sevoflurane inhalation adminis‐
tered by an anesthesiologist via laryngeal insufflation to attain deep sedation for outpatient
GIE procedures. All patients were adequately sedated with sevoflurane, and no intravenous
line was needed. Time to awakening, discharge, and complication rate in the sevoflurane group
were significantly lower than in the combination of midazolam, fentanyl, and ketamine, as
well as in the propofol alone groups. This report suggested that deep sedation with sevoflurane
insufflation for pediatric outpatient GIE procedure is as safe as conventional sedation techni‐
ques [77].
Consequently, Meretoja and colleagues compared anesthesia with sevoflurane or halothane
for bronchoscopy or gastroscopy, or both in 120 infants and children. All pediatric patients
were assigned to receive either 7% sevoflurane or 3% halothane in 66% nitrous oxide in oxygen
for induction of anesthesia. Induction time and psychomotor recovery as well as the incidence
of nausea/vomiting and cardiac arrhythmia in the sevoflurane group were significantly lower
than in the halothane group. This study confirmed that the use of sevoflurane was better than
the use of halothane for bronchoscopy and gastroscopy procedures in pediatric patients [78].
5.13.2. Desflurane
Desflurane is an ether inhalational anesthetic agent. It offers the advantage of precise control
over depth of anesthesia along with a rapid, predictable, and clear-headed recovery with
minimal postoperative adverse events. It also has advantages when used in extremes of age
and in obese patients. Desflurane is generally used for the maintenance of balanced general
anesthesia because of its rapid recovery. Currently, the use of desflurane may increase the
direct costs of anesthetic care [79]. However, no significant differences were demonstrated
between desflurane and sevoflurane in the late recovery period.
6. Post-anesthesia care
Blood pressure, heart rate, respiratory rate, oxygen saturation, and level of consciousness are
monitored and documented at least every 15 min or less, for a minimum of 30 min after the
last dose of sedation drug. These parameters should be monitored and noted in the recovery
period. Moreover, the patients should be monitored for at least 2 h after the last dose of a
reversal drug. All patients will be discharged from the recovery room once the discharge
criteria are completed. Generally, the majority of sedated patients would complete an accept‐
able score on or before 1 h after GIE procedure. Most delays after satisfactory scores were due
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to nonmedical causes [80]. In ambulatory cases, the presence of an escort must be confirmed,
and the patients should not drive for at least 24 h.
7. Conclusion
GIE procedure requires some forms of anesthesia. To date, sedation for GIE procedure can be
effectively and safely performed by anesthesiologist or nonanesthetic personnel with appro‐
priate patient selection and monitoring. The new anesthetic drugs and monitoring equipments
for safety and efficacy are available. However, pre-anesthetic evaluation and preparation,
anesthetic drugs used, monitoring practices and post-anesthesia management are still essential
for the anesthesia innovations in GIE procedures.
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